View source for 6tsd


==Crystal structure of human coxsackievirus A24v in complex with pentavalent inhibitor ME0752==
<StructureSection load='6tsd' size='340' side='right'caption='[[6tsd]], [[Resolution|resolution]] 1.81&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[6tsd]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Coxsackievirus_A24 Coxsackievirus A24]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TSD OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6TSD FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.81&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=HEZ:HEXANE-1,6-DIOL'>HEZ</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SIA:O-SIALIC+ACID'>SIA</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6tsd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tsd OCA], [https://pdbe.org/6tsd PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6tsd RCSB], [https://www.ebi.ac.uk/pdbsum/6tsd PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6tsd ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/V9VEF3_9ENTO V9VEF3_9ENTO] 
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Coxsackievirus A24 variant (CVA24v) and human adenovirus 37 (HAdV-37) are leading causative agents of the severe and highly contagious ocular infections acute hemorrhagic conjunctivitis and epidemic keratoconjunctivitis, respectively. Currently, neither vaccines nor antiviral agents are available for treating these diseases, which affect millions of individuals worldwide. CVA24v and HAdV-37 utilize sialic acid as attachment receptors facilitating entry into host cells. Previously, we and others have shown that derivatives based on sialic acid are effective in preventing HAdV-37 binding and infection of cells. Here, we designed and synthesized novel pentavalent sialic acid conjugates and studied their inhibitory effect against CVA24v and HAdV-37 binding and infection of human corneal epithelial cells. The pentavalent conjugates are the first reported inhibitors of CVA24v infection and proved efficient in blocking HAdV-37 binding. Taken together, the pentavalent conjugates presented here form a basis for the development of general inhibitors of these highly contagious ocular pathogens.

Pentavalent Sialic Acid Conjugates Block Coxsackievirus A24 Variant and Human Adenovirus Type 37-Viruses That Cause Highly Contagious Eye Infections.,Johansson E, Caraballo R, Mistry N, Zocher G, Qian W, Andersson CD, Hurdiss DL, Chandra N, Thompson R, Frangsmyr L, Stehle T, Arnberg N, Elofsson M ACS Chem Biol. 2020 Oct 16;15(10):2683-2691. doi: 10.1021/acschembio.0c00446., Epub 2020 Sep 16. PMID:32845119<ref>PMID:32845119</ref>

From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 6tsd" style="background-color:#fffaf0;"></div>
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Coxsackievirus A24]]
[[Category: Large Structures]]
[[Category: Stehle T]]
[[Category: Zocher G]]